Document Detail

Galacto-oligosaccharides are bifidogenic and safe at weaning: a double-blind randomized multicenter study.
MedLine Citation:
PMID:  19172129     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The primary objective of this study was to determine the bifidogenic effect of galacto-oligosaccharides (GOS) in a follow-on formula and the effects on other intestinal bacteria. Secondary objectives were the effects on stool characteristics, growth, and general well-being. PARTICIPANTS AND METHODS: In a multicenter, double-blind study, 159 healthy infants, formula-fed at enrollment (at 4-6 months), were randomized to an experimental follow-on formula supplemented with 5 g/L (GOS) (77 infants), or to a standard follow-on formula (control, 82 infants). Infants were evaluated at enrollment (study day 1 = sd1), after 6 weeks (study day 2 = sd2), and after an additional 12 weeks (study day 3 = sd3). At each study day, a fresh stool sample for the bacterial counts was collected, and the growth parameters were measured. At sd2, urinary specimens were collected for the evaluation of urinary osmolarity. RESULTS: At sd2 and sd3, the GOS group had a higher median number (colony-forming units per gram of stool) of bifidobacteria than did the control group (sd2 GOS 9.2 x 10(9) vs control 4.4 x 10(9), P = 0.012); (sd3 GOS 7.2 x 10(9) vs control 2.4 x 10(9), P = 0.027). Other bacteria did not show any significant differences between the 2 groups at all study days. The GOS produced softer stools but had no effect on stool frequency. The urinary osmolarity (mOsm/L) at sd2 was comparable in both groups. Supplementation had no influence on the incidence of gastrointestinal side effects or on the growth of the infants. CONCLUSIONS: These data indicate that the addition of GOS (5 g/L) to a follow-on formula positively influences the bifidobacteria flora and the stool consistency in infants during the supplementation period at weaning. No local or systemic side effects were recorded.
Silvia Fanaro; Berit Marten; Rossana Bagna; Vittorio Vigi; Claudio Fabris; Luis Peña-Quintana; Federico Argüelles; Katharina E Scholz-Ahrens; Günther Sawatzki; Richard Zelenka; Jürgen Schrezenmeir; Michael de Vrese; Enrico Bertino
Related Documents :
21103029 - A comparative investigation of an in vitro and clinical test of the bifidogenic effect ...
8583289 - The three-week-old piglet as a model animal for studying protein digestion in human inf...
23856009 - Maternal exposure to combustion generated pm inhibits pulmonary th1 maturation and conc...
3572619 - Bone mineralization and growth in term infants fed soy-based or cow milk-based formula.
12949309 - Visual, cognitive, and language assessments at 39 months: a follow-up study of children...
18541569 - Dietary nucleotides and fecal microbiota in formula-fed infants: a randomized controlle...
1045979 - Consistency and change in styles of mothering.
21894349 - Survival and long-term neurodevelopmental outcome of the extremely preterm infant. a sy...
12367819 - Programming of sympathoadrenal function.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of pediatric gastroenterology and nutrition     Volume:  48     ISSN:  1536-4801     ISO Abbreviation:  J. Pediatr. Gastroenterol. Nutr.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-27     Completed Date:  2009-04-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211545     Medline TA:  J Pediatr Gastroenterol Nutr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  82-8     Citation Subset:  IM    
Neonatal Intensive Care Unit, University of Ferrara, Ferrara, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bifidobacterium / drug effects,  growth & development*
Colony Count, Microbial
Double-Blind Method
Feces / microbiology
Galactose / administration & dosage*,  adverse effects
Infant Formula / administration & dosage*
Intestines / microbiology
Oligosaccharides / administration & dosage*,  adverse effects
Osmolar Concentration
Reg. No./Substance:
0/Oligosaccharides; 0/Placebos; 26566-61-0/Galactose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  British paediatric surveillance unit study of biliary atresia: outcome at 13 years.
Next Document:  Zinc therapy for diarrhoea improves growth among Bangladeshi infants 6 to 11 months of age.